Literature DB >> 9461620

Catalytic and FAD-binding residues of mitochondrial very long chain acyl-coenzyme A dehydrogenase.

M Souri1, T Aoyama, G F Cox, T Hashimoto.   

Abstract

Very long-chain acyl-CoA dehydrogenase (VLCAD) is one of four flavoproteins which catalyze the initial step of the mitochondrial beta-oxidation spiral. By sequence comparison with other acyl-CoA dehydrogenases, Glu-422 of VLCAD has been presumed to be the catalytic residue that abstracts the alpha-proton in the alphabeta-dehydrogenation reaction. Replacing Glu-422 with glutamine (E422Q) caused a loss of enzyme activity by preventing the formation of a charge transfer complex between VLCAD and palmitoyl-CoA. This result provides further evidence for Glu-422 being part of the active site of VLCAD. F418L is a disease-causing mutation in human VLCAD deficiency. Unlike wild-type VLCAD, F418L and F418V contained no bound FAD when expressed at extremely high levels in the baculovirus expression system. Although F418T and F418Y bound FAD at a level similar to that of wild-type VLCAD, both showed reduced Vmax values toward palmitoyl-CoA, most likely due to a decrease in the rate of enzyme-bound FAD reduction. These data suggest that Phe-418 is involved in the binding and subsequent reduction of FAD. FAD-deficient VLCADs (F418L, F418V, and apo-VLCAD) showed increased sensitivity to trypsinization. Loss of FAD may change the folding of VLCAD subunit.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9461620     DOI: 10.1074/jbc.273.7.4227

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  6 in total

1.  Expression and characterization of mutations in human very long-chain acyl-CoA dehydrogenase using a prokaryotic system.

Authors:  Eric S Goetzman; Yudong Wang; Miao He; Al-Walid Mohsen; Brittani K Ninness; Jerry Vockley
Journal:  Mol Genet Metab       Date:  2007-03-19       Impact factor: 4.797

2.  Fatty Acid Oxidation Is Required for Myxococcus xanthus Development.

Authors:  Hannah A Bullock; Huifeng Shen; Tye O Boynton; Lawrence J Shimkets
Journal:  J Bacteriol       Date:  2018-04-24       Impact factor: 3.490

3.  Genetic basis for correction of very-long-chain acyl-coenzyme A dehydrogenase deficiency by bezafibrate in patient fibroblasts: toward a genotype-based therapy.

Authors:  S Gobin-Limballe; F Djouadi; F Aubey; S Olpin; B S Andresen; S Yamaguchi; H Mandel; T Fukao; J P N Ruiter; R J A Wanders; R McAndrew; J J Kim; J Bastin
Journal:  Am J Hum Genet       Date:  2007-10-29       Impact factor: 11.025

4.  Clear correlation of genotype with disease phenotype in very-long-chain acyl-CoA dehydrogenase deficiency.

Authors:  B S Andresen; S Olpin; B J Poorthuis; H R Scholte; C Vianey-Saban; R Wanders; L Ijlst; A Morris; M Pourfarzam; K Bartlett; E R Baumgartner; J B deKlerk; L D Schroeder; T J Corydon; H Lund; V Winter; P Bross; L Bolund; N Gregersen
Journal:  Am J Hum Genet       Date:  1999-02       Impact factor: 11.025

5.  Compared effects of missense mutations in Very-Long-Chain Acyl-CoA Dehydrogenase deficiency: Combined analysis by structural, functional and pharmacological approaches.

Authors:  Stéphanie Gobin-Limballe; Ryan P McAndrew; Fatima Djouadi; Jung-Ja Kim; Jean Bastin
Journal:  Biochim Biophys Acta       Date:  2010-01-12

6.  Structural basis for substrate fatty acyl chain specificity: crystal structure of human very-long-chain acyl-CoA dehydrogenase.

Authors:  Ryan P McAndrew; Yudong Wang; Al-Walid Mohsen; Miao He; Jerry Vockley; Jung-Ja P Kim
Journal:  J Biol Chem       Date:  2008-01-28       Impact factor: 5.157

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.